Oscar Rene Colegio
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Oscar Rene Colegio has a total of 391 co-authors. Here are the top co-authors by number of shared publications:
- Stephanie C. Eisenbarth
The Department Medicine, Division of Allergy and Immunology Northwestern University Feinberg School of Medicine Chicago Illinois USA
6 shared publications - Mike Wang
Yale University
5 shared publications Jennifer M. McNiff
Department of Dermatology, Yale University School of Medicine , New Haven, CT 06510
4 shared publicationsJoyce Y. Cheng
Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut
4 shared publicationsJustin J. Leitenberger
4 shared publicationsAnne Marie Rhebergen
Department of Dermatology, Yale University School of Medicine. New Haven, CT, 06520, USA
3 shared publications
Latest Publications
- Open Access
Functionally and Metabolically Divergent Melanoma-Associated Macrophages Originate from Common Bone-Marrow Precursors
Tumor-associated macrophages (TAMs) can be widely heterogeneous, based on their ontogeny and function, and driven by the tissue-specific niche. TAMs are highly abundant in the melanoma tumor microenvironment (TME), usually correlating with worse prognoses. However, the understanding of their diversity may be harnessed for therapeutic purposes. Here, we used the clinically relevant YUMM1.7 model to study melanoma TAM origin and dynamics during tumor progression. In i.d. YUMM1.7 tumors, we identified distinct TAM subsets based on F4/80 expression, with the F4/80high fraction increasing over time and displaying a tissue-resident-like phenotype. While skin-resident macrophages showed mixed ontogeny, F4/80+ TAM subsets in the melanoma TME originated almost exclusively from bone-marrow precursors. A multiparametric analysis of the macrophage phenotype showed a temporal divergence of the F4/80+ TAM subpopulations, which also differed from the skin-resident subsets and their monocytic precursors. Overall, the F4/80+ TAMs displayed co-expressions of M1- and M2-like canonical markers, while RNA sequencing showed differential immunosuppressive and metabolic profiles. Gene-set enrichment analysis (GSEA) revealed F4/80high TAMs to rely on oxidative phosphorylation, with increased proliferation and protein secretion, while F4/80low cells had high pro-inflammatory and intracellular signaling pathways, with lipid and polyamine metabolism. Overall, we provide an in-depth characterization of and compelling evidence for the BM-dependency of melanoma TAMs. Interestingly, the transcriptomic analysis of these BM-derived TAMs matched macrophage subsets with mixed ontogeny, which have been observed in other tumor models. Our findings may serve as a guide for identifying potential ways of targeting specific immunosuppressive TAMs in melanoma.
Open AccessFunctionally and Metabolically Divergent Melanoma-Associated Macrophages Originate from Common Bone-Marrow Precursors
Tumor-associated macrophages (TAMs) can be widely heterogeneous, based on their ontogeny and function, and driven by the tissue-specific niche. TAMs are highly abundant in the melanoma tumor microenvironment (TME), usually correlating with worse prognoses. However, the understanding of their diversity may be harnessed for therapeutic purposes. Here, we used the clinically relevant YUMM1.7 model to study melanoma TAM origin and dynamics during tumor progression. In i.d. YUMM1.7 tumors, we identified distinct TAM subsets based on F4/80 expression, with the F4/80high fraction increasing over time and displaying a tissue-resident-like phenotype. While skin-resident macrophages showed mixed ontogeny, F4/80+ TAM subsets in the melanoma TME originated almost exclusively from bone-marrow precursors. A multiparametric analysis of the macrophage phenotype showed a temporal divergence of the F4/80+ TAM subpopulations, which also differed from the skin-resident subsets and their monocytic precursors. Overall, the F4/80+ TAMs displayed co-expressions of M1- and M2-like canonical markers, while RNA sequencing showed differential immunosuppressive and metabolic profiles. Gene-set enrichment analysis (GSEA) revealed F4/80high TAMs to rely on oxidative phosphorylation, with increased proliferation and protein secretion, while F4/80low cells had high pro-inflammatory and intracellular signaling pathways, with lipid and polyamine metabolism. Overall, we provide an in-depth characterization of and compelling evidence for the BM-dependency of melanoma TAMs. Interestingly, the transcriptomic analysis of these BM-derived TAMs matched macrophage subsets with mixed ontogeny, which have been observed in other tumor models. Our findings may serve as a guide for identifying potential ways of targeting specific immunosuppressive TAMs in melanoma.
- 25 August 2021
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 47 (11) , 1428-1432
Skin Cancer Incidence in Organ Transplant Recipients Referred for Benign Skin Conditions
BACKGROUND: Solid organ transplant recipients (SOTRs) are at ∼100-fold increased risk for developing skin cancers compared with the general population, with increased morbidity and mortality. These patients are closely followed by dermatology; however, it is unclear how referral reasons from nondermatologic providers affect care in these patients. OBJECTIVE: This study examines the reason SOTRs are referred to dermatologic care by nondermatologic providers as a potential predictor of nonmelanoma skin cancer (NMSC) outcomes. MATERIALS AND METHODS: A retrospective case–control study was conducted with the records of 353 adult SOTRs referred to a specialized transplant dermatology clinic within an academic tertiary care center between 2007 and mid-2012. RESULTS: Eighty-one patients were diagnosed with 491 total premalignant and malignant skin lesions. A considerable proportion of patients diagnosed with NMSC were referred for benign skin conditions such as rash or acne. CONCLUSION: These results indicate that some SOTRs referred to dermatology for benign skin disorders are incidentally diagnosed with cutaneous malignancies; this is concerning given that referrals for benign skin conditions may delay appropriate care for cutaneous malignancies and preventative care. Better risk stratification, improved interdisciplinary collaboration, and prompt referrals for dermatologic care are needed in the care of SOTRs.
- 25 August 2021
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 47 (11) , 1428-1432
Skin Cancer Incidence in Organ Transplant Recipients Referred for Benign Skin Conditions
BACKGROUND: Solid organ transplant recipients (SOTRs) are at ∼100-fold increased risk for developing skin cancers compared with the general population, with increased morbidity and mortality. These patients are closely followed by dermatology; however, it is unclear how referral reasons from nondermatologic providers affect care in these patients. OBJECTIVE: This study examines the reason SOTRs are referred to dermatologic care by nondermatologic providers as a potential predictor of nonmelanoma skin cancer (NMSC) outcomes. MATERIALS AND METHODS: A retrospective case–control study was conducted with the records of 353 adult SOTRs referred to a specialized transplant dermatology clinic within an academic tertiary care center between 2007 and mid-2012. RESULTS: Eighty-one patients were diagnosed with 491 total premalignant and malignant skin lesions. A considerable proportion of patients diagnosed with NMSC were referred for benign skin conditions such as rash or acne. CONCLUSION: These results indicate that some SOTRs referred to dermatology for benign skin disorders are incidentally diagnosed with cutaneous malignancies; this is concerning given that referrals for benign skin conditions may delay appropriate care for cutaneous malignancies and preventative care. Better risk stratification, improved interdisciplinary collaboration, and prompt referrals for dermatologic care are needed in the care of SOTRs.
- Open Access
- 24 May 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-11
Topical arginase inhibition decreases growth of cutaneous squamous cell carcinoma
Cutaneous squamous cell carcinomas (cSCC) are among the most commonly diagnosed malignancies, causing significant morbidity and mortality. Tumor-associated macrophage (TAM) expression of arginase is implicated in tumor progression, and therapeutic use of arginase inhibitors has been studied in various cancers. However, investigating potential cSCC immunotherapies including arginase inhibition in pre-clinical models is hampered by the lack of appropriate tumor models in immunocompetent mice. PDV is a cSCC cell line derived from chemical carcinogenesis of mouse keratinocytes. PDVC57 cells were derived from a PDV tumor in C57BL/6 (B6) mice. Unlike PDV, PDVC57 tumors grow consistently in B6 mice, and have increased TAMs, decreased dendritic and T cell intra-tumor infiltration. Arginase inhibition in cSCC tumors using Nω-hydroxy-nor-arginine (nor-NOHA) reduced tumor growth in B6 mice but not immunodeficient Rag1-deficient mice. nor-NOHA administration increased dendritic and T cell tumor-infiltration and PD-1 expression. The combination of nor-NOHA and anti-PD-1 therapy with nivolumab enhanced anti-PD-1 therapeutic efficacy. This study demonstrates the therapeutic potential of transcutaneous arginase inhibition in cSCC. A competent immune microenvironment is required for tumor growth inhibition using this arginase inhibitor. Synergistic co-inhibition of tumor growth in these results, supports further examination of transcutaneous arginase inhibition as a therapeutic modality for cSCC.
- 24 May 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-11
Open AccessTopical arginase inhibition decreases growth of cutaneous squamous cell carcinoma
Cutaneous squamous cell carcinomas (cSCC) are among the most commonly diagnosed malignancies, causing significant morbidity and mortality. Tumor-associated macrophage (TAM) expression of arginase is implicated in tumor progression, and therapeutic use of arginase inhibitors has been studied in various cancers. However, investigating potential cSCC immunotherapies including arginase inhibition in pre-clinical models is hampered by the lack of appropriate tumor models in immunocompetent mice. PDV is a cSCC cell line derived from chemical carcinogenesis of mouse keratinocytes. PDVC57 cells were derived from a PDV tumor in C57BL/6 (B6) mice. Unlike PDV, PDVC57 tumors grow consistently in B6 mice, and have increased TAMs, decreased dendritic and T cell intra-tumor infiltration. Arginase inhibition in cSCC tumors using Nω-hydroxy-nor-arginine (nor-NOHA) reduced tumor growth in B6 mice but not immunodeficient Rag1-deficient mice. nor-NOHA administration increased dendritic and T cell tumor-infiltration and PD-1 expression. The combination of nor-NOHA and anti-PD-1 therapy with nivolumab enhanced anti-PD-1 therapeutic efficacy. This study demonstrates the therapeutic potential of transcutaneous arginase inhibition in cSCC. A competent immune microenvironment is required for tumor growth inhibition using this arginase inhibitor. Synergistic co-inhibition of tumor growth in these results, supports further examination of transcutaneous arginase inhibition as a therapeutic modality for cSCC.
- 1 April 2020
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 82 (4) , 996-998
Belatacept reduces skin cancer risk in kidney transplant recipients
- 1 April 2020
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 82 (4) , 996-998
Belatacept reduces skin cancer risk in kidney transplant recipients
- Open Access
- 4 February 2020
- Published by MDPI AG in Applied Sciences
- Vol. 10 (3) , 1024
Photoacoustic Imaging of Tattoo Inks: Phantom and Clinical Evaluation
Photoacoustic imaging (PAI) is a novel hybrid imaging modality that provides excellent optical contrast with the spatial resolution of ultrasound in vivo. The method is widely being investigated in the clinical setting for diagnostic applications in dermatology. In this report, we illustrate the utility of PAI as a non-invasive tool for imaging tattoos. Ten different samples of commercially available tattoo inks were examined for their optoacoustic properties in vitro. In vivo PAI of an intradermal tattoo on the wrist was performed in a healthy human volunteer. Black/gray, green, violet, and blue colored pigments provided higher levels of PA signal compared to white, orange, red, and yellow pigments in vitro. PAI provided excellent contrast and enabled accurate delineation of the extent of the tattoo in the dermis. Our results reveal the photoacoustic properties of tattoo inks and demonstrate the potential clinical utility of PAI for intradermal imaging of tattoos. PAI may be useful as a clinical adjunct for objective preoperative evaluation of tattoos and potentially to guide/monitor laser-based tattoo removal procedures.
- 4 February 2020
- Published by MDPI AG in Applied Sciences
- Vol. 10 (3) , 1024
Open AccessPhotoacoustic Imaging of Tattoo Inks: Phantom and Clinical Evaluation
Photoacoustic imaging (PAI) is a novel hybrid imaging modality that provides excellent optical contrast with the spatial resolution of ultrasound in vivo. The method is widely being investigated in the clinical setting for diagnostic applications in dermatology. In this report, we illustrate the utility of PAI as a non-invasive tool for imaging tattoos. Ten different samples of commercially available tattoo inks were examined for their optoacoustic properties in vitro. In vivo PAI of an intradermal tattoo on the wrist was performed in a healthy human volunteer. Black/gray, green, violet, and blue colored pigments provided higher levels of PA signal compared to white, orange, red, and yellow pigments in vitro. PAI provided excellent contrast and enabled accurate delineation of the extent of the tattoo in the dermis. Our results reveal the photoacoustic properties of tattoo inks and demonstrate the potential clinical utility of PAI for intradermal imaging of tattoos. PAI may be useful as a clinical adjunct for objective preoperative evaluation of tattoos and potentially to guide/monitor laser-based tattoo removal procedures.
- 1 December 2019
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 81 (6) , 1417-1419
Retrospective cohort study of anatomic localization of cutaneous squamous cell carcinomas in solid organ transplant recipients compared with immunocompetent patients
- 1 December 2019
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 81 (6) , 1417-1419
Retrospective cohort study of anatomic localization of cutaneous squamous cell carcinomas in solid organ transplant recipients compared with immunocompetent patients
- Open Access
- 1 September 2019
- Published by Elsevier in JAAD Case Reports
- Vol. 5 (9) , 773-775
Nail changes, lymphedema, and respiratory symptoms
- 1 September 2019
- Published by Elsevier in JAAD Case Reports
- Vol. 5 (9) , 773-775
Open AccessNail changes, lymphedema, and respiratory symptoms
- Open Access
Human keratinocyte carcinomas have distinct differences in their tumor-associated macrophages
- 1 June 2019
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 80 (6) , 1774-1776
Trends in scholarly productivity of dermatology faculty by academic status and gender
- 1 June 2019
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 80 (6) , 1774-1776
Trends in scholarly productivity of dermatology faculty by academic status and gender
- 14 March 2019
- Published by H1 Connect
Faculty Opinions recommendation of Tofacitinib treatment and molecular analysis of cutaneous sarcoidosis.
This study, though limited to a single case, demonstrates the novel use of a JAK1/3 inhibitor (tofacitinib) to induce complete remission in treatment-resistant cutaneous sarcoidosis. This case highlights well the use of RNA sequencing when addressing a multi-therapy-resistant disease in the current era of rational personalized medicine; as such, it reinforces the idea that though morphologically similar diseases can be clustered under an umbrella term such as "cutaneous sarcoidosis", the underlying molecular deviations are varied, which can/should be elucidated and appropriately targeted.
- 14 March 2019
- Published by H1 Connect
Faculty Opinions recommendation of Tofacitinib treatment and molecular analysis of cutaneous sarcoidosis.
This study, though limited to a single case, demonstrates the novel use of a JAK1/3 inhibitor (tofacitinib) to induce complete remission in treatment-resistant cutaneous sarcoidosis. This case highlights well the use of RNA sequencing when addressing a multi-therapy-resistant disease in the current era of rational personalized medicine; as such, it reinforces the idea that though morphologically similar diseases can be clustered under an umbrella term such as "cutaneous sarcoidosis", the underlying molecular deviations are varied, which can/should be elucidated and appropriately targeted.